Kākoʻo nā hopena mai ka hoʻāʻo ʻana i ka phase2 i ka manaʻo e hoʻonui ka hoʻokele subcutaneous o IFN-β no ka mālama ʻana iā COVID-19 i ka wikiwiki o ka hoʻihoʻi ʻana a hoʻemi i ka make..
ʻO ke kūlana koʻikoʻi i hōʻike ʻia e ka maʻi maʻi COVID-19 ua pono e ʻimi i nā ala like ʻole no ka mālama ʻana i nā hihia koʻikoʻi COVID-19. Ke hoʻāʻo ʻia nei kekahi mau lāʻau lapaʻau hou a hoʻohana hou ʻia nā lāʻau i loaʻa. Corticosteroids ua ʻike ʻia he pono. Hoʻohana ʻia ka interferon therapy no nā maʻi viral e like me ka hepatitis. Hiki ke hoʻohana ʻia ka IFN e kūʻē iā SARS CoV-2 ma COVID-19?
I nā hoʻokolohua preclinical ma mua, ua hōʻoia ʻo IFN i ka maikaʻi e kūʻē iā SARS CoV a MERS virus. I Iulai 2020, ua hōʻike ʻia ka hoʻokele ʻana o Interferon-β ma o ka nebulization (e like me ka pulmonary inhalation) ala e hōʻike i nā hopena hoʻohiki i ka mālama ʻana i nā hihia koʻikoʻi COVID-19 e pili ana i ka ʻikepili mai ka hoʻokolohua lapaʻau ʻelua. 1,2.
I kēia manawa, ʻo ka hōʻike hou loa e pili ana i ka ʻikepili mai ka pae 2 hoʻokolohua lapaʻau i mālama ʻia ma luna o 112 mau mea maʻi me COVID-19 halemai ma Pitié-Salpêtrière ma Paris, Farani e hōʻike ana i ka hoʻokele ʻana o IFN-β ma o ke ala subcutaneous e hoʻonui ai i ka helu hoʻōla a hoʻemi i ka make ma COVID-19 hihia 3.
ʻO Interferon (IFN) nā protein i hūnā ʻia e nā pūnaewele hoʻokipa i ka pane ʻana i nā maʻi maʻi e hōʻailona i nā cell ʻē aʻe no ka hele ʻana o ka maʻi. Ua ʻike ʻia ka pane ʻeha nui i kekahi o nā maʻi maʻi COVID-19 e pili ana me ka pane IFN-1 pilikia a me ka blockade. IFN-β huna huna. Hoʻohana ʻia ia ma China no ka mālama ʻana i ka maʻi pneumonia viral ma muli o SARS CoV akā ʻaʻole i hoʻohālikelike ʻia kona hoʻohana ʻana 4.
Ke holomua nei ka hoʻokolohua lapaʻau ʻāpana 3 no ka hoʻohana ʻana i nā Interferon (IFN) i ka mālama ʻana i nā maʻi maʻi COVID-19. ʻO ka ʻae ʻia e hilinaʻi ʻia inā paha nā hopena hope loa i loko o ka palena i ʻae ʻia e nā mea hoʻoponopono.
***
Sources:
- NHS 2020. Nūhou- ʻO ka lāʻau inhaled e pale aku i nā maʻi maʻi COVID-19 e ʻoi aku ka hewa ma ka hoʻokolokolo ʻo Southampton. Hoʻopuka ʻia ma ka 20 Iulai 2020. Loaʻa ma ka pūnaewele ma https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/News-and-updates/Articles/Inhaled-drug-prevents-COVID-19-patients-getting-worse-in-Southampton-trial.aspx Loaʻa i ka 12 Pepeluali 2021.
- Monk PD., Marsden RJ., Tear VJ., et al., 2020. Ka palekana a me ka pono o ka inhaled nebulised interferon beta-1a (SNG001) no ka mālama ʻana i ka maʻi SARS-CoV-2: he randomised, double-blind, placebo- hoʻomalu ʻia, ka hoʻāʻo pae 2. ʻO ka Lancet Respiratory Medicine, loaʻa ma ka pūnaewele 12 Nowemapa 2020. DOI: https://doi.org/10.1016/S2213-2600(20)30511-7
- Dorgham K., Neumann AU., et al 2021. E noʻonoʻo ana i ka maʻi Interferon-β pilikino no COVID-19. Antimicrobial Agents Chemotherapy. Hoʻouna ʻia ma ka pūnaewele 8 Pepeluali 2021. DOI: https://doi.org/10.1128/AAC.00065-21
- Mary A., Hénaut L., Macq PY., et al 2020. ʻO ke kumu no ka mālama ʻana i ka COVID-19 e ka Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience. Frontiers in Pharmacology., 30 Nowemapa 2020. DOI:https://doi.org/10.3389/fphar.2020.592543.
***
